An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
NCT01703988
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Spinal Muscular Atrophy
Interventions
DRUG:
Nusinersen
Sponsor
Biogen